Looks like you’re on the UK site. Choose another location to see content specific to your location
Roche’s Alecensa shows benefits in treatment of lung cancer
Roche has announced the findings of a phase III clinical trial showing the benefits offered by its drug Alecensa as a first-line treatment for a specific type of lung cancer.
Data from the ALEX study showed that Alecensa improved rates of progression-free survival by more than half compared to an established alternative when given as a first-line treatment for people with ALK-positive advanced non-small cell lung cancer (NSCLC).
Roche's drug was shown to lower the risk of tumour spread or growth in the brain or central nervous system, making this the second phase III head-to-head study to show the advantages of Alecensa in the treatment of ALK-positive lung cancer.
Data from the ALEX study will be used to support Roche's application for full approval of Alecensa as an initial treatment for ALK-positive advanced NSCLC in Europe, an indication for which it was granted conditional authorisation in February.
Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "These results significantly improve upon the standard of care for this disease, extending the average time that people lived without their disease worsening from less than a year to more than two years."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard